194 related articles for article (PubMed ID: 37594284)
1.
Park J; Kim LH; Lee JM; Choi S; Son YJ; Hwang HJ; Shin SJ
Microbiol Spectr; 2023 Aug; 11(5):e0182523. PubMed ID: 37594284
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
[TBL] [Abstract][Full Text] [Related]
3. A Rapid Screening Assay for Clarithromycin-Resistant Mycobacterium avium Complex Using Melting Curve Analysis with Nonfluorescent Labeled Probes.
Aoki A; Jinno H; Ogawa K; Nakagawa T; Inagaki T; Wajima T; Okamoto Y; Uchiya KI
Microbiol Spectr; 2023 Feb; 11(1):e0432622. PubMed ID: 36622171
[TBL] [Abstract][Full Text] [Related]
4. Intracellular and in vivo activities of oxazolidinone drugs against Mycobacterium avium complex infection.
Lee JM; Kim LH; Kim SY; Jhun BW; Lee W; Shin SJ
Sci Rep; 2023 Nov; 13(1):20631. PubMed ID: 37996500
[TBL] [Abstract][Full Text] [Related]
5. Development of a rapid detection method for the macrolide resistance gene in
Inagaki T; Asahi S; Ogawa K; Nakagawa T; Ohkura T; Osada Y; Nikai T; Yamada K; Yagi T; Uchiya K-i
Microbiol Spectr; 2024 Apr; 12(4):e0233923. PubMed ID: 38363108
[TBL] [Abstract][Full Text] [Related]
6. Macrolide resistant Mycobacterium avium complex pulmonary disease following clarithromycin and ethambutol combination therapy.
Ito Y; Miwa S; Shirai M; Kanai M; Fujita K; Ohba H; Iwaizumi E; Oshima T; Kojima S; Suda T; Hayakawa H
Respir Med; 2020 Aug; 169():106025. PubMed ID: 32442113
[TBL] [Abstract][Full Text] [Related]
7. A Clofazimine-Containing Regimen Confers Improved Treatment Outcomes in Macrophages and in a Murine Model of Chronic Progressive Pulmonary Infection Caused by the
Lee JM; Park J; Choi S; Jhun BW; Kim SY; Jo KW; Hong JJ; Kim LH; Shin SJ
Front Microbiol; 2020; 11():626216. PubMed ID: 33519787
[TBL] [Abstract][Full Text] [Related]
8. Studies on macrolide antibiotics I. Synthesis and antibacterial activity of erythromycin A 9-O-substituted oxime ether derivatives against Mycobacterium avium complex.
Nishimoto A; Narita K; Ohmoto S; Takahashi Y; Yoshizumi S; Yoshida T; Kado N; Okezaki E; Kato H
Chem Pharm Bull (Tokyo); 2001 Sep; 49(9):1120-7. PubMed ID: 11558597
[TBL] [Abstract][Full Text] [Related]
9. Resumption/efficacy and safety of an azithromycin-containing regimen against Mycobacterium avium complex lung disease in patients who experienced adverse effects with a clarithromycin-containing regimen.
Kobayashi T; Tsuyuguchi K; Yoshida S; Kimura Y; Tsuji T; Minomo S; Kurahara Y; Inoue Y; Suzuki K
Respir Investig; 2021 Mar; 59(2):212-217. PubMed ID: 33436352
[TBL] [Abstract][Full Text] [Related]
10. Multidrug Antibiotic Therapy for a Non-Human Immunodeficiency Virus-Infected Patient With Clarithromycin-Resistant Disseminated Mycobacterium avium Complex Disease.
Kawamura A; Sugawara H; Fukuchi T; Tanaka A
Cureus; 2021 Oct; 13(10):e18967. PubMed ID: 34815908
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics, Treatment Outcomes, and Resistance Mutations Associated with Macrolide-Resistant Mycobacterium avium Complex Lung Disease.
Moon SM; Park HY; Kim SY; Jhun BW; Lee H; Jeon K; Kim DH; Huh HJ; Ki CS; Lee NY; Kim HK; Choi YS; Kim J; Lee SH; Kim CK; Shin SJ; Daley CL; Koh WJ
Antimicrob Agents Chemother; 2016 Nov; 60(11):6758-6765. PubMed ID: 27572413
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic drug monitoring in the treatment of Mycobacterium avium complex lung disease.
Koh WJ; Jeong BH; Jeon K; Lee SY; Shin SJ
Am J Respir Crit Care Med; 2012 Oct; 186(8):797-802. PubMed ID: 22878282
[TBL] [Abstract][Full Text] [Related]
13. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS
J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877
[TBL] [Abstract][Full Text] [Related]
14. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
Griffith DE; Brown-Elliott BA; Langsjoen B; Zhang Y; Pan X; Girard W; Nelson K; Caccitolo J; Alvarez J; Shepherd S; Wilson R; Graviss EA; Wallace RJ
Am J Respir Crit Care Med; 2006 Oct; 174(8):928-34. PubMed ID: 16858014
[TBL] [Abstract][Full Text] [Related]
15. An
Sonawane VV; Ruth MM; Pennings LJ; Svensson EM; Wertheim HFL; Hoefsloot W; van Ingen J
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0273020. PubMed ID: 33972258
[TBL] [Abstract][Full Text] [Related]
16. Development of Macrolide Resistance and Reinfection in Refractory Mycobacterium avium Complex Lung Disease.
Jhun BW; Kim SY; Moon SM; Jeon K; Kwon OJ; Huh HJ; Ki CS; Lee NY; Shin SJ; Daley CL; Koh WJ
Am J Respir Crit Care Med; 2018 Nov; 198(10):1322-1330. PubMed ID: 29877739
[TBL] [Abstract][Full Text] [Related]
17. Controversies in the management of Mycobacterium avium complex infection in AIDS patients.
Peloquin CA
Ann Pharmacother; 1993; 27(7-8):928-37. PubMed ID: 8364280
[TBL] [Abstract][Full Text] [Related]
18. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of aminoglycosides, clofazimine, d-cycloserine and dapsone against 83 Mycobacterium avium complex clinical isolates.
Huang CC; Wu MF; Chen HC; Huang WC
J Microbiol Immunol Infect; 2018 Oct; 51(5):636-643. PubMed ID: 28705770
[TBL] [Abstract][Full Text] [Related]
20. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
